Despite Early Low Awareness, Physicians Forecast Swift Adoption of Novo Nordisk's Wegovy in MASH, According to Spherix Global Insights

Core Insights - Novo Nordisk's Wegovy has been approved as a second treatment for metabolic dysfunction-associated steatohepatitis (MASH), marking a significant advancement in addressing a condition with a large patient population and unmet medical needs [1] - A recent study indicates that while initial awareness of Wegovy's approval is modest, there is strong confidence among physicians regarding its potential role in MASH treatment, with 65% planning to prescribe it within three months [2] Market Context - Wegovy enters a competitive market led by Madrigal Pharmaceuticals' Rezdiffra, the first FDA-approved therapy for MASH, which has established a strong adoption base among specialists [3] - The study highlights distinct treatment preferences among physicians, with Wegovy preferred for moderate fibrosis (F2) patients due to its weight loss benefits, while combination therapy with Rezdiffra is favored for advanced fibrosis (F3) patients [4] Physician Insights - For F2 patients, 43% of physicians prefer Wegovy monotherapy, citing its effectiveness in reducing liver fat and fibrosis, while 30% prefer Rezdiffra for its antifibrotic properties [4] - In the case of F3 patients, 43% of physicians advocate for a combination of Rezdiffra and Wegovy, reflecting skepticism about the adequacy of monotherapy for this high-risk group [4] Future Monitoring - The positive early prescribing intent and clear positioning of Wegovy across patient segments suggest it will significantly impact MASH care, with ongoing monitoring of prescriber sentiment and treatment strategies planned by Spherix Global Insights [4]